Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate
Executive Summary
Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.